IDEA: Innovating Decisions and Empowering Action in Diabetes Management

Program Description

This unique educational initiative, IDEA, will create educational and awareness programs for both clinicians and patients. The goal of this initiative is to help the diabetes community understand continuous glucose monitoring (CGM), report interpretations, and how to use this information to optimize therapeutic management. This educational activity provides a guide for the development and distribution of teaching and learning resources to make the use of CGM Glucose Pattern Summary and Blood Glucose Pattern Summary reports best practice standards in the care of patients with diabetes.

The IDEA Project is a major educational initiative that will change the way CGM data is interpreted and used in diabetes care by health care professionals and by patients with diabetes. The project has several goals:

  • Improve the understanding of continuous glucose monitoring as well as report interpretations
  • Optimize the many facets of diabetes management including lifestyle and medication changes
  • Analyze opportunities for practice transformation, increased shared decision-making, and more personalized care

Background

AACE has developed several professional consensus statements regarding collection and interpretation of glucose data.  Starting in 2001, with the American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control, AACE has been at the forefront of the collection and use of blood glucose information (1).  As glucose practices and information change, the AACE position on diabetes and glucose management evolved to support these changes (2). Within the last two years, AACE has updated its Consensus statements on Outpatient Glucose Monitoring and developed a Consensus statement on Continuous Glucose Monitoring (3, 4). After the development of the AACE Consensus on Continuous Glucose Monitoring, the writing committee further recommended the development of standardized glucose reporting in a format that was easy to understand for both healthcare clinicians and patients. This will facilitate understanding of CGM reporting by patients and support education, training and shared decision-making (5). AACE is recommending standard reports that are consistent with the CGM Consensus Conference findings. The reports include:

  • CGM Glucose Pattern Summary
  • CGM Ambulatory Glucose Pattern Summary
  • Blood Glucose Pattern Summary
  • Ambulatory Glucose Pattern Summary

Despite proven benefits and advances in technology that have improved the convenience and usability of blood glucose monitors and continuous glucose monitoring (CGM) devices, these technologies remain under-utilized in the diabetes community. Among patients with type 2 diabetes, only half test their blood glucose daily, and approximately a third of patients with type 1 diabetes test their glucose fewer than 3 times daily, when the recommended frequency is 1-4 times per day for type 2 and 6-8 times per day for type 1 diabetes. In addition, only 15% of patients with type 1 diabetes and a negligible proportion of type 2 patients use a CGM device. Utilization of glucose data has not been consistent in the past but use of personal CGM has increased over the past year, yet still varied in the clinical arena with debate on the value of measuring versus the rapid development of continuous measurement technology. However, a better understanding of the meaningful use of various glucose parameters in clinical decision-making as well as the personal use of this information by patients struggling for better diabetes control is the main goal for glucose measurement and interpretation.

Target Audience

  • Endocrinologists
  • Primary care clinicians, including Physician Assistants and Nurse Practitioners
  • Diabetes Educators (including CDE, RN, PharmD)
  • Patients and Caregivers living with Diabetes

Learning Objectives

1. Discuss the limitations of A1c as a marker of diabetes control

2. Explain the merits of evaluating time in range and hypoglycemic and hyperglycemic excursions and as well as A1c

3. Describe how glucose monitoring devices facilitate prevention, detection, and prompt treatment of hypoglycemia

4. Discuss improved patient outcomes associated with glucose monitoring as well as technological advances that have improved the ease of use of these devices

Additional information
Available for MOC Points?: 
No
Course summary
Available credit: 
  • 3.00 AMA
Course opens: 
01/10/2020
Course expires: 
01/10/2023
Rating: 
5

Content Contributors

Content Authors

  • George Grunberger, MD, FACP, FACE, Program Co-Chairman
  • Guillermo Umpierrez, MD, FACP, Program Co-Chairman
  • Timothy Bailey, MD
  • Richard Bergenstal, MD
  • Lawrence Blonde, MD, FACE, MACE
  • Jenna Brothers, PAC
  • Bruce Buckingham, MD, FACE
  • Ji Hyun Chun, MPAS, PA-C, BC-ADM
  • Daniel Einhorn, MD, FACP, FACE
  • Wendy McLaughlin, PAC
  • Ann Peters, MD, CDE
  • Archana R. Sadhu, MD, FACE

 

Planners

American Association of Clinical Endocrinologist (AACE)

  • Elizabeth Lepkowski, MATD, AACE Chief Learning Officer
  • Michele Lentz, AACE Chief Strategic Alliances Officer
  • Beverly Hastings, AACE Live Learning Manager
  • Michelle Michelotti, MHA, Director of Online Learning and Technology

American Association of Diabetes Educators (AADE)

  • Nancy D’Hondt, RPh

American College of Clinical Pharmacy (ACCP)

  • Daniel Aistrope, PharmD, BC-ACP
  • Shelly Enders, PharmD

American Society of Endocrine Physician Assistants (ASEPA) / American Academy of Physician Assistants (AAPA)

  • Ji Hyun Chun, MPAS, PA-C, BC-ADM
  • Jenna Brothers, PAC
  • Wendy McLaughlin, PAC

Diabetes Patient Advocacy Coalition (DPAC)

  • Stewart Perry, Vic Chair, DPAC

International Diabetes Center (IDC)

  • Richard Bergenstal, MD
  • Gregg Simonson, PhD
  • Dana Gershenoff, MS, RD, CDE

The Leona M. and Harry B. Helmsley Charitable Trust

  • David Panzier

T1D Exchange

  • Alicia McAuliffe-Fogarty

The diaTribe Foundation

  • Ms. Kelly Close

The France Foundation

  • Theodore Bruno, MD
  • Ailene Cantelmi
  • Amanda Noe
  • Heather Tarbox, MPH
  • Eve Wilson, PhD

Accreditation

The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association of Clinical Endocrinologists (AACE) designates this enduring material for a maximum of 3 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Association of Clinical Endocrinologists (AACE) recognizes that you are a life-long learner who has chosen to engage in continuing medical education to identify or fill a gap in knowledge, skill or performance. As part of AACE’s duty to you as a learner, you have the right to expect that your continuing medical education experience with AACE includes:

CONTENT that:

  • Promotes improvements or quality in healthcare;
  • Is Valid, reliable and accurate;
  • Offers balanced presentations that are free of commercial bias for or against a product/service;
  • Is vetted through a process that resolves any conflicts of interest of planners, teachers or authors;
  • Is driven and based on learning needs, not commercial interests;
  • Addresses the stated objectives or purpose; and
  • Is evaluated for its effectiveness in meeting the identified educational need.

A LEARNING ENVIRONMENT that:

  • Supports learners’ ability to meet their individual needs;
  • Respects and attends to any special needs of the learners;
  • Respects the diversity of groups of learners; and
  • Is free of promotional, commercial and/or sales activities.

 

DISCLOSURE of:

  • Relevant financial relationships planners, teachers and authors have with commercial interests related to the content of the activity; and
  • Commercial support (funding or in-kind resources) of the activity.

Commercial Support

The educational program is provided by educational grants from Abbott, AstraZeneca, Dexcom, Janssen, Mannkind, and Novo Nordisk.


For questions regarding this CME activity, please contact the AACE CME Department through the 'Contact Us' webform or cme@aace.com.

Copyright 2019, AACE. All rights reserved. No part of this enduring material may be reproduced or transmitted in any other form or by any other means, electronic or mechanical, without first obtaining written permission from AACE.

Available Credit

  • 3.00 AMA

Accreditation Period

Course opens: 
01/10/2020
Course expires: 
01/10/2023
Please login or register to take this course.